Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population | Zendy

Elizabeth R. Stevens | Zendy; Kimberly A. Nucifora | Zendy; Holly Hagan | Zendy; Ashly E. Jordan | Zendy; Jennifer Uyei | Zendy; Bilal Khan | Zendy; Kirk Dombrowski | Zendy; Don C. Des Jarlais | Zendy; R. Scott Braithwaite | Zendy

Open Access

Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population

Author(s) -

Elizabeth R. Stevens,

Kimberly A. Nucifora,

Holly Hagan,

Ashly E. Jordan,

Jennifer Uyei,

Bilal Khan,

Kirk Dombrowski,

Don C. Des Jarlais,

R. Scott Braithwaite

Publication year - 2019

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciz726

Subject(s) - medicine , cost effectiveness , population , syringe , economic evaluation , opioid use disorder , quality adjusted life year , psychological intervention , cost effectiveness analysis , hepatitis c , prison , cost–benefit analysis , intervention (counseling) , environmental health , emergency medicine , virology , psychiatry , opioid , risk analysis (engineering) , psychology , ecology , pathology , biology , receptor , criminology

There are too many plausible permutations and scale-up scenarios of combination hepatitis C virus (HCV) interventions for exhaustive testing in experimental trials. Therefore, we used a computer simulation to project the health and economic impacts of alternative combination intervention scenarios for people who inject drugs (PWID), focusing on direct antiviral agents (DAA) and medication-assisted treatment combined with syringe access programs (MAT+).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research